Topic

Blue Cross Blue Shield (BCBS Association)

A collection of 1330 issues

How to Get Fintepla (fenfluramine) Covered by Blue Cross Blue Shield in Washington: Appeals Process, REMS Requirements, and State Protections

Answer Box: Getting Fintepla Covered by Blue Cross Blue Shield in Washington Fintepla (fenfluramine) requires prior authorization from Blue Cross Blue Shield with mandatory REMS enrollment and baseline echocardiography. To get approval: (1) Complete REMS enrollment at FinteplaREMS.com with baseline ECHO, (2) Submit PA with diagnosis confirmation (Dravet G40.

How to Get Cosentyx (secukinumab) Covered by Blue Cross Blue Shield of Illinois: Complete Coding, PA, and Appeals Guide

Answer Box: Getting Cosentyx Approved in Illinois Cosentyx (secukinumab) requires prior authorization through Blue Cross Blue Shield of Illinois for 2024-2025, using HCPCS code J3247 for IV formulation or J3590 for subcutaneous. Submit PA requests with proper ICD-10 codes (L40.0 for plaque psoriasis, L40.50-59 for psoriatic arthritis), tuberculosis

How to Get Gamifant (Emapalumab-lzsg) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Timeline and Appeal Guide

Answer Box: Getting Gamifant Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield requires prior authorization for Gamifant (emapalumab-lzsg) with documented HLH diagnosis using 5 of 8 HLH-2004 criteria OR genetic confirmation, plus failure/intolerance to conventional therapy (etoposide, dexamethasone, cyclosporine). Standard PA decisions take 14-30 days;

How to Get Brineura (Cerliponase Alfa) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Brineura Covered by Blue Cross Blue Shield in Pennsylvania Brineura (cerliponase alfa) requires prior authorization from Blue Cross Blue Shield plans in Pennsylvania, including Highmark and Independence Blue Cross. Coverage is approved for pediatric patients with confirmed CLN2 disease (TPP1 deficiency) when administered at specialized centers by

How to Get Jakafi (Ruxolitinib) Covered by Blue Cross Blue Shield in Florida: Complete Prior Authorization and Appeals Guide

Answer Box: Fastest Path to Jakafi Approval in Florida Jakafi (ruxolitinib) requires prior authorization through Florida Blue Cross Blue Shield and is subject to quantity limits (60 tablets per fill). For myelofibrosis, submit PA with confirmed diagnosis, platelet count ≥50,000/mcL, and monitoring plan. For polycythemia vera, add documented

Get Emflaza (Deflazacort) Covered by Blue Cross Blue Shield of Texas: Forms, Appeals & IRO Process

Answer Box: Getting Emflaza Covered by BCBS Texas Blue Cross Blue Shield of Texas requires prior authorization for Emflaza (deflazacort) with specific DMD criteria. Your fastest path: (1) Confirm genetic DMD diagnosis and CK levels ≥10x normal, (2) Document prednisone trial/failure if switching, (3) Submit PA via BCBS Texas

How to Get Venclexta (venetoclax) Covered by Blue Cross Blue Shield in New York: Complete PA Guide and Appeal Process

Quick Answer: Getting Venclexta Covered in New York Blue Cross Blue Shield of New York requires prior authorization for Venclexta (venetoclax), typically with step therapy requirements for BTK inhibitors like ibrutinib in CLL cases. Three-step path: (1) Your oncologist submits PA via Availity Essentials with diagnosis, TLS monitoring plan, and

How to Get Retevmo (Selpercatinib) Covered by Blue Cross Blue Shield in New York: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Retevmo Covered by Blue Cross Blue Shield in New York Retevmo (selpercatinib) requires prior authorization from Blue Cross Blue Shield in New York for RET fusion-positive NSCLC and RET-mutant thyroid cancers. The fastest path to approval: (1) Confirm RET testing with an FDA-approved companion diagnostic, (2) Submit

How to Get Orfadin (nitisinone) Covered by Blue Cross Blue Shield in California: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Orfadin Covered by Blue Cross Blue Shield in California Blue Cross Blue Shield plans in California require prior authorization for Orfadin (nitisinone) as a specialty drug, with coverage limited to confirmed hereditary tyrosinemia type 1 (HT-1) at doses ≤2 mg/kg per day. Your fastest path to

How to Get Vitrakvi (Larotrectinib) Covered by Blue Cross Blue Shield in Ohio: Timeline, Appeals, and NTRK Testing Requirements

Quick Answer: Getting Vitrakvi Covered in Ohio Blue Cross Blue Shield in Ohio typically requires prior authorization for Vitrakvi (larotrectinib), with 15 business days for standard review or 72 hours for expedited cases. Success depends on complete NTRK fusion testing documentation, proof of metastatic/unresectable disease, and evidence of failed